ArticleScience translational medicine2021
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury.Circulation research · 2026Article
- Inhaled bovine lactoferrin modulates the p47phox-MPO-NETosis axis in acute lung injury: implications for bioengineered nanomedicine in respiratory infections.Frontiers in immunology · 2026Article
- MAP3K3 Contributes to Myocardial Ischemia/Reperfusion Injury by Promoting Myeloid Cell Diapedesis through TAL1/JAM-A Pathway.Theranostics · 2026Article
- Novel insights into diagnosis and management of hyperreactivity: a narrative review.Journal of thoracic disease · 2025Review
- Targeting JNK1/2 and P38 Mitogen-Activated Protein Kinases With Pazopanib Mitigates Bleomycin-Induced Lung Fibrosis.Archiv der Pharmazie · 2025Article
- Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS).Respiratory research · 2024Review
- Reactive Oxygen Species and Strategies for Antioxidant Intervention in Acute Respiratory Distress Syndrome.Antioxidants (Basel, Switzerland) · 2023Review
- Pazopanib Is a Potential Treatment for Coronavirus-Induced Lung Injuries.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- MiR-20a-5p facilitates cartilage repair in osteoarthritis via suppressing mitogen-activated protein kinase kinase kinase 2.Bioengineered · 2022Article
- Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment-From Mice to Men.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 2 countries.
Qianying YuanVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-4972-3264
Abdul BasitVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-7881-806X
Wenhua LiangDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0002-1391-8238
Rihao QuDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-8258-8287
Yi LuanVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-3044-6700
Chunguang RenVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-3245-1159
Ao LiVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.
Xin XuDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0002-4834-7922
Xiaoqing LiuDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0003-3059-7293
Chun YangDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0001-6148-0237
Andrew KuoVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-7263-8658
Richard PierceVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-5941-8805
Longbo ZhangDepartment of Neurosurgery, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-9077-3239
Benjamin TurkDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-9275-4069
Xin HuDepartment of Biostatistics, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-1097-3300
Fangyong LiDepartment of Biostatistics, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-3171-7592
Weixue CuiDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0003-2146-6208
Run LiDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0002-9505-2713
Danxia HuangDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0002-9505-2713
Lili MoDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.ORCID 0000-0003-3030-7225
William C SessaVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-5759-1938
Patty J LeeDepartment of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-9906-1628
Yuval KlugerDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-3035-071X
Bing SuShanghai Institute of Immunology, Shanghai Jiaotong University, Shanghai 200025, China. dan.wu@yale.edu drjianxing.he@gmail.com wenwen.tang@yale.edu bingsu@sjtu.edu.cn.ORCID 0000-0003-0871-7666
Wenwen TangVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA. dan.wu@yale.edu drjianxing.he@gmail.com wenwen.tang@yale.edu bingsu@sjtu.edu.cn.ORCID 0000-0001-9234-4385
Jianxing HeDepartment of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China. dan.wu@yale.edu drjianxing.he@gmail.com wenwen.tang@yale.edu bingsu@sjtu.edu.cn.ORCID 0000-0003-1737-8192
Dianqing WuVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA. dan.wu@yale.edu drjianxing.he@gmail.com wenwen.tang@yale.edu bingsu@sjtu.edu.cn.ORCID 0000-0002-7342-5961
Yale University · USFirst Affiliated Hospital of Guangzhou Medical University · CNShanghai Jiao Tong University · CN
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MPediatric Critical Care Scientist Development ProgramK12HD047349 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HEATHER T. KEENAN, Kevin M Watt · 2004 to 2026
$17.0MSignaling mechanisms and functions related to patho-physiology of vascular, lung and blood systemsR35HL135805 · NHLBI · YALE UNIVERSITY · PI WU, DIANQING · 2017 to 2023
$6.4MThe role of MAP3K2/3 in modulating neutrophil ROS release and its translational potentialR01HL145152 · NHLBI · YALE UNIVERSITY · PI TANG, WENWEN · 2019 to 2022
$1.7MEFFICIENT METHODS FOR CALIBRATION, CLUSTERING, VISUALIZATION AND IMPUTATION OF LARGE scRNA-seq DATAR01GM131642 · NIGMS · YALE UNIVERSITY · PI KLUGER, YUVAL · 2019 to 2022
$1.6MMechanisms of Endothelial Cell Dysfunction in Critically Ill ChildrenK08HL136898 · NHLBI · YALE UNIVERSITY · PI PIERCE, RICHARD W · 2019 to 2023
$780kNCATS NIH HHS UL1 TR001863NHLBI NIH HHS K08 HL136898NHLBI NIH HHS R01 HL145152NHLBI NIH HHS R35 HL135805NICHD NIH HHS K12 HD047349NIGMS NIH HHS R01 GM131642
Abstract
Acute lung injury (ALI) causes high mortality and lacks any pharmacological intervention. Here, we found that pazopanib ameliorated ALI manifestations and reduced mortality in mouse ALI models and reduced edema in human lung transplantation recipients. Pazopanib inhibits mitogen-activated protein kinase kinase kinase 2 (MAP3K2)- and MAP3K3-mediated phosphorylation of NADPH oxidase 2 subunit p47
Indexed as
Acute Lung InjuryAnimalsHumansHydrogen PeroxideIndazolesMAP Kinase Kinase Kinase 2MAP Kinase Kinase Kinase 3MiceNADPH OxidasesPhosphorylationPyrimidinesReactive Oxygen SpeciesSulfonamidesHydrogen PeroxideIndazolesMAP3K2 protein, humanMAP3K3 protein, humanMAP Kinase Kinase Kinase 2MAP Kinase Kinase Kinase 3NADPH OxidasespazopanibPyrimidinesReactive Oxygen SpeciesSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.